Atopic Dermatitis

An expert dermatologist provides key takeaways and the real-world significance of dupilumab use for the treatment of atopic dermatitis.

LEO Pharma presented long-term data from an interim analysis of its ECZTEND 5-year extension trial, showing no new safety signals.

A poster from the 2022 American Academy of Dermatology Annual Meeting gathered the real-world data around patients using dupilumab to treat atopic dermatitis.

Dr Andrew Blauvelt reviews key highlights and clinical implications from the LIBERTY AD OLE study assessing the effect of long-term dupilumab treatment on efficacy improvements in adults with moderate to severe atopic dermatitis.

Medications, plants, and more may play a significant role in systemic contact dermatitis.

Andrew Blauvelt, MD, MBA, reviews recent advances in the therapeutic landscape for moderate to severe atopic dermatitis.

In their session, “Translating Evidence into Practice: Atopic Dermatitis Guidelines,” at the current AAD annual meeting, Jonathan I. Silverberg, MD, PhD, MPH, FAAD, Peter A. Lio, MD, FAAD, Andrew Blauvelt, MD, FAAD, and Robert Sidbury, MD, MPH, FAAD, discuss updates in new therapies, clinical pearls, and potential co-morbidities.

Determining the cause of a child's rash is important to proper diagnosis and management. Allergic contact dermatitis and eczema are 2 of most common causes.

In a poster at the 2022 SOC scientific symposium, Andrew Alexis, MD, MPH, examined the efficacy of one AD drug against race and ethnicity.

An expert dermatologist evaluates the role of dupilumab in decreasing the clinical burden of severe atopic dermatitis on patients and their caregivers and shares insight on the future outlook of dupilumab in disease management.

Benjamin Lockshin, MD, FAAD, reviews key findings from a phase 2 trial evaluating the safety and efficacy of single-dose dupilumab in children with severe atopic dermatitis.

Benjamin Lockshin, MD, FAAD, comments on the significance of recent expansions of therapeutics options for patients with atopic dermatitis and unmet needs in the field.

Data from the RELIEVE-AD study show long-term control and treatment satisfaction.

Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.

Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.

A recent study aimed to identify whether using specific serum biomarkers could predict therapeutic response in patients with atopic dermatitis.

Concluding their focused discussion on JAK inhibitors in atopic dermatitis, panelists share advice on the optimal selection based on route of administration and use of these agents.

A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.

Cara Therapeutics announced that difelikefalin—its treatment for moderate to severe pruritus in atopic dermatitis patients—was selected for a late-breaker presentation at the 2022 American Academy of Dermatology annual meeting.

A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.

Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.

Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.

Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.

Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.

What is the relationship between mental disorders and atopic dermatitis? Investigators from a recent study endeavored to find out.

Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.

A review of topical JAK inhibitor ruxolitinib.

The American Academy of Dermatology’s newest guideline focuses on awareness of other health conditions associated with atopic dermatitis in adult patients.

If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate to severe atopic dermatitis for young children 6 months to 5 years old.

Click to answer this week's poll on the newly released AAD guidelines on AD comorbidites.